Average 126% gains – NO losers!?  
An epic crash is all but inevitable, but these dark times can offer staggering opportunities.

Today, Dr. Martin Weiss reveals "Crash Profit Trades" that could have produced average gains of 126% even when stocks tumbled.

All with NO losing trades!

Click Here to Discover the Secret.
>>>

CHM Insider Trading (Chimeric Therapeutics)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$2,940.00
Insider Selling (Last 12 Months): A$0.00

Chimeric Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Chimeric Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Chimeric Therapeutics Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 03/11/2021 11:04 AM ET

This chart shows the closing price history over time for CHM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!

Chimeric Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/29/2022Leslie (Mi Ok) ChongInsiderBuy30,000A$0.10A$2,940.00
3/25/2022Leslie (Mi Ok) ChongInsiderIssued3,905A$0.15A$585.75
8/4/2021George MatchamInsiderBuy500,000A$0.33A$166,000.00
3/8/2021Cynthia ElkinsInsiderBuy24,800A$0.32A$7,886.40
See Full Table
A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.

SEC Filings (Institutional Ownership Changes) for Chimeric Therapeutics (ASX:CHM)

Chimeric Therapeutics logo
Chimeric Therapeutics Limited researches, develops, and commercializes cell therapies for cancer in Australia. The company develops CLTX CAR T cell therapy that is in Phase I clinical study for Glioblastoma; and CDH17 CAR T, which is in preclinical study for neuroendocrine tumours, as well as colorectal, pancreatic, and gastric cancer. It has a strategic partnership with OncoBay Clinical for the development program of CLTX CAR T. The company was incorporated in 2020 and is based in Carlton, Australia.
Read More on Chimeric Therapeutics

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Chimeric Therapeutics?

Chimeric Therapeutics' top insider shareholders include:
  1. Cynthia Elkins (Insider)
  2. George Matcham (Insider)
  3. Leslie (Mi Ok) Chong (Insider)
Learn More about top insider investors at Chimeric Therapeutics.
Average 126% gains – NO losers!?  
An epic crash is all but inevitable, but these dark times can offer staggering opportunities.

Today, Dr. Martin Weiss reveals "Crash Profit Trades" that could have produced average gains of 126% even when stocks tumbled.

All with NO losing trades!

Click Here to Discover the Secret.
>>>